Quanta Dialysis Technologies, a leader in transforming kidney care through its award-winning Quanta Dialysis System, has successfully closed its oversubscribed Series E Preferred Stock financing round, raising more than $60 million of additional capital.

Led by Novo Holdings, Glenview Capital and b2venture, with broad participation by existing shareholders, this latest funding round underscores strong investor confidence in Quanta's market potential to revolutionize the treatment of kidney disease across a variety of settings.